MARKET

ADXS

ADXS

Advaxis Inc
OTCQX
1.380
-0.020
-1.43%
Closed 10:06 03/22 EDT
OPEN
1.360
PREV CLOSE
1.400
HIGH
1.380
LOW
1.360
VOLUME
259
TURNOVER
355
52 WEEK HIGH
56.80
52 WEEK LOW
1.000
MARKET CAP
2.51M
P/E (TTM)
-0.1631
1D
5D
1M
3M
1Y
5Y
Ayala Pharma to continue Phase 2/3 Ringside study in desmoid tumors
Seeking Alpha · 03/03 13:24
BRIEF-Ayala Pharmaceuticals Announces Continuation Of Ringside Phase 2/3 Study In Desmoid Tumors
Reuters · 03/03 13:04
Advaxis GAAP EPS of -$8.46, revenue of $0.25M
Seeking Alpha · 02/10 12:45
Ayala sees last day of trading as merger with Advaxis takes place
Seeking Alpha · 01/18 19:24
Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQ
Ayala Pharmaceuticals Inc (NASDAQ: AYLA) and Advaxis Inc (OTC: ADXS) have announced a merger agreement. 
Benzinga · 10/19/2022 16:29
Ayala rises 16% on all-stock merger with Advaxis to focus on cancer drugs
Seekingalpha · 10/19/2022 11:08
BRIEF-Ayala Pharmaceuticals And Advaxis Enter Into Merger Agreement
Reuters · 10/19/2022 10:37
Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement in All-Stock Deal
Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers and Advaxis, Inc.
Benzinga · 10/19/2022 10:33
More
About ADXS
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of Listeria monocytogenes (Lm)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets to engage the patient's immune system to destroy tumor cells. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Its Lm platform technology has clinical activity in several programs. These Lm strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment (TME) to enable the T-cells to eliminate tumors.

Webull offers kinds of Advaxis, Inc. stock information, including OTCQX:ADXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADXS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADXS stock methods without spending real money on the virtual paper trading platform.